Research programme: osteoarthritis therapy - Genentech
Latest Information Update: 02 Nov 2005
At a glance
- Originator Genentech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Osteoarthritis in USA (unspecified route)
- 21 May 2001 New profile
- 21 May 2001 Preclinical development for Osteoarthritis in USA (Unknown route)